Acuta Capital Partners, LLC Gh Research PLC Transaction History

Acuta Capital Partners, LLC

  • $98.8 Million
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023
BUY
$7.88 - $12.74 $12,434 - $20,103
1,578 Added 0.65%
244,828 $2.91 Million
Q2 2022

Aug 15, 2022
SELL
$8.99 - $19.87 $1.59 Million - $3.5 Million
-176,382 Reduced 42.03%
243,250 $2.43 Million
Q4 2021

Feb 14, 2022
BUY
$14.1 - $27.9 $371,986 - $736,057
26,382 Added 6.71%
419,632 $9.79 Million
Q3 2021

Nov 15, 2021
BUY
$16.51 - $23.68 $4.02 Million - $5.76 Million
243,250 Added 162.17%
393,250 $8.68 Million
Q2 2021

Aug 16, 2021
BUY
$19.25 - $21.73 $2.89 Million - $3.26 Million
150,000 New
150,000 $3.26 Million

Others Institutions Holding GHRS

# of Institutions
32
Shares Held
27.8M
Call Options Held
2.8K
Put Options Held
3.8K
View Full List

About GH Research PLC

GHRS Quotes by TradingView
  • Ticker GHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,020,800
  • Market Cap $369M
  • Description
  • GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH0...
More about GHRS
Track This Portfolio

Track Acuta Capital Partners, LLC Portfolio

Follow Acuta Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acuta Capital Partners, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email